
San Rocco Therapeutics Files Civil RICO Lawsuit Against Monied Interests of Gene Therapy





trialsitenews



Follow

Staff at TrialSite | Quality Journalism

May. 3, 2023, 9:00 p.m.

A civil action has been filed, charging violations of the Federal Racketeering and Corrupt Organizations Act (RICO), fraudulent inducement and unfair business practices in the United States District Court in Massachusetts. The defendants are Nick Leschly, Mitchell Finer, Phillip Reilly, Third Rock Ventures, bluebird bio Inc., and 2seventy Bio Inc. This lawsuit is linked to the TrialSite’s ongoing tracking of the San Rocco Therapeutics (SRT), formerly Errant Gene Therapeutics, and bluebird legal conflict. See [“A FamilyMan’s battle against the forefront of capitalist medicine: the case of Errant Gene Therapeutics.”](#)

Nick Leschly, the former CEO of **bluebird bio**, profited \$24,000,000, alone in 2018, making him the highest compensated pharma CEO in the world. The complaint alleges that his earnings were a direct result of fraudulent and corrupt *RICO* violations at the expense of the health of patients. **Bluebird bio**’s *gene therapy* was approved in August 2022 to treat *Thalassemia* for \$2.8 million per patient. **SRT** has a safer *gene therapy* product that will cost over \$2,000,000 less at \$700,000.

San Rocco Therapeutics (SRT) is a biotechnology research company and a worldwide leader in *gene therapy*. **SRT** filed the 72-page *RICO* complaint on Thursday, April 27, 2023.

SRT brought actions against Defendants for civil violations of the Federal Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. § 1964(a), (b), (c), and (d) (*"Federal RICO"*) and Mass. Gen. Laws ch. 93A, § 11.

In addition, **SRT** brings a cause of action against Defendants for fraudulent inducement of, including conspiracy to fraudulently induce, **SRT** to execute a confidential settlement agreement on November 2, 2020.

Phillip Reilly is a Venture Partner at **Third Rock Ventures** and former Chief Medical Officer of **bluebird**. **Mitchell Finer** is the ex-chief scientific officer of **bluebird**. As background for the *RICO* filing, it is mentioned that Jan Leschly was the CEO of SmithKline Beecham during the period in which they were fined \$3,000,000,000 by the US Department of Justice. Deception about clinical trials resulted in over 60,000 children committing suicide.

SRT was founded by Patrick Girondi in 1993. Girondi embarked on a mission to cure his son Rocco of *Thalassemia*. For 30 years, **SRT** has been repeatedly beleaguered by sabotage and other unfair medical and legal acts.

According to Patrick Girondi, "The simple reason for the delay for patients comes down to two events. The first

occurrence was when **Third Rock Ventures** paid \$35,000,000 for a faulty product and the second was when greed pushed the defendants to steal the **SRT** *gene therapy* secrets to fix their jealousy.”

SRT, headquartered in the US and Italy, was the first company to get Orphan Drug designation for *Thalassemia* in the US and Europe. **SRT** has the longest track record of treating U.S. patients and is the only company with experience in both harsh and soft chemotherapeutic prep-regimens. **SRT** has conducted *gene therapy* clinical trials longer than any entity in the U.S.A. **SRT** is the first to produce a commercial batch (8-10 patients) of *gene therapy* for *Sickle Cell Disease* and *Thalassemia*.

In the U.S.A., there are over 100,000 patients afflicted by *Sickle Cell Disease*, a disease that predominantly affects the African American population. Thus, these crimes considerably affect ethnic communities, including Latins, Mediterraneanans and Africans.

In addition to legal fees and other costs, **SRT** seeks \$1 billion in monetary damages.

Gironi, also an artist, has used his music and writing to bring awareness to his mission. Each album of his Orphan’s Dream band tells a story about research and the experiences of people affiliated with the **SRT** project, some for decades.

Mr. Gironi’s book “Flight of the Rondone – High School Dropout VS Big Pharma: The Fight to Save My Son’s Life” was released last year and made the #1 Wall Street

Journal Bestseller List, reaching #1 on three Amazon bestseller lists; #1 on Barnes and Noble; and top 100 on USA Today.

Girondi has 4 more books in the pipeline with Skyhorse Publishing; his next scheduled release is in November.

All of **Girondi's** efforts go hand-in-hand with **SRT's** mission to cure *Sickle Cell Disease* and *Beta Thalassemia*.

[Click here](#) to see the publicly filed complaint.

Gene Therapy

Hemoglobin

Thalassemia

Sickle Cell

Company

About Us
Terms of Service
Privacy Policy
Contact Us

TrialSiteNews

159 W Broadway, Suite 200
Salt Lake City, UT 84101

Publish on TrialSite

Writing Best Practices